CONBA(SH:600572)2014-04-21 16:00Financial Performance - Net profit attributable to shareholders rose by 32.67% to CNY 138,502,813.90 year-on-year[10] - Operating income grew by 9.14% to CNY 732,629,094.31 compared to the same period last year[10] - Basic and diluted earnings per share increased by 30.77% to CNY 0.17[10] - Total operating revenue for Q1 2014 was CNY 732,629,094.31, an increase of 9.1% from CNY 671,295,540.48 in the same period last year[39] - Net profit for Q1 2014 reached CNY 146,155,433.66, representing a 28.3% increase compared to CNY 113,948,200.55 in Q1 2013[40] - Investment income for the reporting period grew by 203.03% year-on-year, mainly due to the disposal of 7.31847 million shares of Zhaoli Pharmaceutical, resulting in an investment gain of 80.6738 million yuan[20] - Investment income for Q1 2014 was CNY 86,280,131.93, significantly higher than CNY 28,472,398.41 in Q1 2013, indicating a strong performance in this area[40] Assets and Liabilities - Total assets increased by 4.93% to CNY 4,673,202,805.47 compared to the end of the previous year[10] - As of March 31, 2014, the company's total assets amounted to RMB 4.67 billion, an increase from RMB 4.45 billion at the beginning of the year[32] - The company's total equity increased to RMB 2.74 billion from RMB 2.59 billion, representing a growth of approximately 5.8%[34] - The total current liabilities rose to RMB 1.13 billion from RMB 1.07 billion, indicating an increase of about 5.5%[34] - The company's cash and cash equivalents increased to RMB 974.95 million from RMB 781.99 million, reflecting a growth of approximately 24.6%[33] - The company's cash and cash equivalents increased to CNY 530,696,910.21 from CNY 368,713,431.19, marking a growth of 43.8%[37] Cash Flow - Cash flow from operating activities decreased by 50.03% to CNY 59,345,798.31 compared to the previous year[10] - Operating cash flow net amount decreased by 50.03% year-on-year, primarily due to increased cash outflows for employee payments and taxes[22] - Cash inflow from operating activities totaled ¥774,555,747.04, down 3.3% from ¥800,660,208.40 in the previous period[45] - Cash outflow from operating activities increased to ¥715,209,948.73, up 4.9% from ¥681,901,071.85[46] - Cash flow from investment activities generated a net inflow of ¥84,190,190.54, a significant improvement from a net outflow of ¥462,412,333.03 in the previous period[46] - The net cash flow from financing activities was ¥54,409,911.41, compared to a net outflow of ¥77,064,252.33 in the previous period[46] Shareholder Information - The total number of shareholders reached 41,635 by the end of the reporting period[14] - The largest shareholder, Kang En Bei Group Co., Ltd., holds 33.32% of the shares[14] - The company issued 106 million A shares through a private placement, with a lock-up period of 36 months for the investors[31] Investments and Acquisitions - The company disposed of 7.31847 million shares of Zhejiang Zuoli Pharmaceutical Co., resulting in a gain of CNY 80,727,611.39[12] - The company is planning a major asset restructuring and has announced the acquisition of shares in Guizhou Bait Pharmaceutical Co., Ltd.[24] - The company completed the acquisition of 35% and 33.30% stakes in Yunnan Xitao Company from Yangying Tang and Biological Valley, respectively, with a projected net profit of RMB 40.23 million for 2012, RMB 44.58 million for 2013, and RMB 48.01 million for 2014[28] Agreements and Commitments - The company has committed to not engaging in any competitive activities with its controlling shareholder during its tenure[25] - The company committed to not engaging in any competition with Zhejiang Zuoli Pharmaceutical Co., Ltd. regarding products derived from medicinal fungi[29] - The company has established a profit compensation agreement for the acquisition, ensuring cash compensation if actual net profits fall below the projected figures[28] - The profit compensation agreement for the acquisition of Kang En Bei Traditional Chinese Medicine Co., Ltd. includes projected net profits for 2011-2014, with 2014's forecast at 61.0738 million yuan[27] Receivables and Prepayments - The company's receivable interest increased by 100.00% compared to the beginning of the year, primarily due to the recognition of interest income from time deposits during the reporting period[17] - Prepayments rose by 60.22% compared to the beginning of the year, mainly due to prepayments for advertising expenses and technology transfer fees by subsidiaries[18] - Other receivables increased by 64.08% compared to the beginning of the year, attributed to an increase in market reserve funds[18] - The company reported a significant increase in accounts receivable, rising to RMB 505.64 million from RMB 409.71 million, an increase of approximately 23.4%[33]